MCM
CRSP icon

MAI Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

MAI Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
8,030
+1,211
+18% +$63.8K ﹤0.01% 1370
2026
Q1 		$324K Buy
6,819
+2,360
+53% +$124K ﹤0.01% 1237
2025
Q4 		$234K Hold
4,459
– – ﹤0.01% 1256
2025
Q3 		$289K Buy
4,459
+1,250
+39% +$71.8K ﹤0.01% 1118
2025
Q2 		$156K Buy
3,209
+144
+5% +$5.57K ﹤0.01% 1292
2025
Q1 		$104K Sell
3,065
-1,518
-33% -$64.3K ﹤0.01% 1390
2024
Q4 		$180K Hold
4,583
– – ﹤0.01% 1176
2024
Q3 		$215K Sell
4,583
-870
-16% -$44.1K ﹤0.01% 989
2024
Q2 		$295K Sell
5,453
-331
-6% -$19.1K ﹤0.01% 997
2024
Q1 		$394K Buy
5,784
+506
+10% +$36.2K ﹤0.01% 888
2023
Q4 		$330K Buy
5,278
+720
+16% +$39.8K ﹤0.01% 838
2023
Q3 		$207K Buy
4,558
+431
+10% +$22.3K ﹤0.01% 952
2023
Q2 		$232K Buy
+4,127
New +$234K ﹤0.01% 915
2022
Q4 		– Sell
-4,157
Closed -$272K – 1036
2022
Q3 		$272K Buy
4,157
+502
+14% +$36.4K 0.01% 730
2022
Q2 		$222K Buy
+3,655
New +$215K ﹤0.01% 775

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAI Capital Management's CRSP Position: Q2 2026 in Review

MAI Capital Management increased its CRISPR Therapeutics (CRSP) stake by 18% in Q2 2026, buying an estimated $63.8K and bringing the position to 8,030 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

MAI Capital Management first reported a position in CRSP in Q2 2022 and has held it in 15 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • MAI Capital Management held 8,030 shares of CRISPR Therapeutics worth $438K as of Q2 2026.
  • MAI Capital Management bought 1,211 CRISPR Therapeutics shares in Q2 2026, an estimated $63.8K.
  • CRISPR Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1370 holding.
  • MAI Capital Management first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.